Stefania L. Ciummo

Chieti, 66100, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Interleukin-30 promotes melanoma spreading and triggers LAG-3 expression and T cell exhaustion.

Interleukin-30 promotes melanoma spreading and triggers LAG-3 expression and T cell exhaustion.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: November 21, 2025

Prostatic fibroblast reprogramming by Interleukin-30 activates prostate cancer metastasis programs.

Prostatic fibroblast reprogramming by Interleukin-30 activates prostate cancer metastasis programs.

Journal: Molecular biomedicine

Published: August 25, 2025

Nanomedicine for cancer patient-centered care.

Nanomedicine for cancer patient-centered care.

Journal: MedComm

Published: July 12, 2024

Prevention of prostate cancer metastasis by a CRISPR-delivering nanoplatform for interleukin-30 genome editing.

Prevention of prostate cancer metastasis by a CRISPR-delivering nanoplatform for interleukin-30 genome editing.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: June 10, 2024

Immunoliposome-based targeted delivery of the CRISPR/Cas9gRNA-IL30 complex inhibits prostate cancer and prolongs survival.

Immunoliposome-based targeted delivery of the CRISPR/Cas9gRNA-IL30 complex inhibits prostate cancer and prolongs survival.

Journal: Experimental & molecular medicine

Published: February 05, 2024

Interleukin-30 subverts prostate cancer-endothelium crosstalk by fostering angiogenesis and activating immunoregulatory and oncogenic signaling pathways.

Interleukin-30 subverts prostate cancer-endothelium crosstalk by fostering angiogenesis and activating immunoregulatory and oncogenic signaling pathways.

Journal: Journal of experimental & clinical cancer research : CR

Published: July 24, 2023

Inactivation of interleukin-30 in colon cancer stem cells via CRISPR/Cas9 genome editing inhibits their oncogenicity and improves host survival.

Inactivation of interleukin-30 in colon cancer stem cells via CRISPR/Cas9 genome editing inhibits their oncogenicity and improves host survival.

Journal: Journal for immunotherapy of cancer

Published: February 27, 2023

CRISPR/Cas9-mediated deletion of Interleukin-30 suppresses IGF1 and CXCL5 and boosts SOCS3 reducing prostate cancer growth and mortality.

CRISPR/Cas9-mediated deletion of Interleukin-30 suppresses IGF1 and CXCL5 and boosts SOCS3 reducing prostate cancer growth and mortality.

Journal: Journal of hematology & oncology

Published: May 27, 2022

Colorectal Cancer-Associated Immune Exhaustion Involves T and B Lymphocytes and Conventional NK Cells and Correlates With a Shorter Overall Survival.

Colorectal Cancer-Associated Immune Exhaustion Involves T and B Lymphocytes and Conventional NK Cells and Correlates With a Shorter Overall Survival.

Journal: Frontiers in immunology

Published: September 16, 2021

Interleukin-30 feeds breast cancer stem cells via CXCL10 and IL23 autocrine loops and shapes immune contexture and host outcome.

Interleukin-30 feeds breast cancer stem cells via CXCL10 and IL23 autocrine loops and shapes immune contexture and host outcome.

Journal: Journal for immunotherapy of cancer

Published: September 09, 2021

The C-X-C Motif Chemokine Ligand 1 Sustains Breast Cancer Stem Cell Self-Renewal and Promotes Tumor Progression and Immune Escape Programs.

The C-X-C Motif Chemokine Ligand 1 Sustains Breast Cancer Stem Cell Self-Renewal and Promotes Tumor Progression and Immune Escape Programs.

Journal: Frontiers in cell and developmental biology

Published: March 31, 2021

Hindering triple negative breast cancer progression by targeting endogenous interleukin-30 requires IFNγ signaling.

Hindering triple negative breast cancer progression by targeting endogenous interleukin-30 requires IFNγ signaling.

Journal: Clinical and translational medicine

Published: November 24, 2020

Showing 1-12 of 14

Last Updated: 09/26/2026